Carrie L. Bourdow

President and Chief Executive Officer

Ms. Bourdow was appointed President, Chief Executive Officer, and member of the Trevena Board of Directors in October 2018, and as Chair of the Board in November 2023. She has served in various senior positions at Trevena since May 2015. She joined the Company as Chief Commercial Officer and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from 2013 until its acquisition by Merck & Co. (MRK), Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across multiple therapeutic areas. Ms. Bourdow previously served as a member of the board of directors for Sesen Bio from February 2020 until March 2023 and as a member of the board of directors for Nabriva Therapeutics plc. (NBRV) from June 2017 until July 2023.

Scott Braunstein, M.D.

Dr. Braunstein joined the Board in September 2018 and was appointed Lead Independent Director in November 2023. Dr. Braunstein is currently Chief Executive Officer and Chairman of the board of directors at Marinus Pharmaceuticals, Inc. (MRNS). Dr. Braunstein is also an Operating Partner at Aisling Capital Management LP, a life sciences private equity firm, where he has served since 2015. From 2015 to 2018, Dr. Braunstein also served as Chief Operating Officer, SVP of Corporate Strategy, and Chief Strategy Officer at Pacira Pharmaceuticals, Inc. (now known as Pacira BioSciences, Inc.) (PCRX), a specialty pharmaceutical company. Dr. Braunstein was previously a healthcare analyst and managing director on the U.S. Equity team of J.P. Morgan Asset Management and served as the portfolio manager for the J.P. Morgan Global Healthcare fund. Dr. Braunstein was responsible for managing investments in pharmaceuticals, biotechnology, and medical devices. Dr. Braunstein is currently a member of the board of directors for Marinus and Caribou Biosciences (CRBU), each a public biotechnology company. Dr. Braunstein previously served as a member of the board of directors of Esperion Therapeutics, Inc. (ESPR), Ziopharm Oncology, Inc. (now known as Alaunos Therapeutics) and Constellation Pharmaceuticals (acquired by MorphoSys). Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. Dr. Braunstein received his M.D. from the Albert Einstein College of Medicine and his B.S. from Cornell University.

Dr. Mark Corrigan

Dr. Corrigan is currently the acting CEO at Tremeau Pharmaceuticals, a company he co-founded in 2016, and has served as a member of its board since its inception. He also serves as a member of the board of directors of Wave Life Sciences. He Chairs the Board of Elios Therapeutics, a private company. In addition, Dr. Corrigan is a visiting professor in the psychiatry department at Harvard's Brigham and Women’s Hospital in Boston, MA. From 2019 to 2021 Dr. Corrigan served as CEO of Correvio Pharma and prior to that role Dr. Corrigan served as Director, President and Chief Executive Officer of Zalicus, Inc. from 2010 to 2014. Formerly, Dr. Corrigan was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc. He also spent 10 years with Pharmacia & Upjohn where he served as Group Vice President of Global Clinical Research and Experimental Medicine. He has served on the board of directors of Cubist Pharmaceuticals, where he chaired the Scientific Committee, Avanir Pharmaceuticals, Inc., Novelion, CoLucid and Nabriva Therapeutics. Before entering the pharmaceutical industry, Dr. Corrigan was in academic research at the University of North Carolina at Chapel Hill School of Medicine. Dr. Corrigan holds a Bachelor of Science from the University of Virginia, as well as an MD from the University of Virginia School of Medicine.

Marvin H. Johnson, Jr.

Mr. Johnson’s professional experience included over 34 years at Merck & Co., predominantly in the area of commercial operations, that spanned a diverse and increasing set of responsibilities. Mr. Johnson held Senior Sales and Marketing leadership positions across multiple therapeutic categories including Diabetes, Acute Care, Neurology, Respiratory, Cardiovascular, Pain Management and Sleep Disorders. His experiences have included leading large scale regional, national and global sales and marketing organizations worth over $3 billion in revenue, and he has extensive experience launching products in the U.S and abroad. Mr. Johnson was most recently Chief Learning Officer at Merck from 2016 until his retirement in October 2018.

Mr. Johnson currently serves on the board of directors of Marinus Pharmaceuticals, Inc. (MRNS). Mr. Johnson is also the Vice Chair on the Board of Trustees for Tabor Children’s Services, Inc. a nonprofit child welfare agency where he has served as a board member since 2014. Since December 2018, Mr. Johnson has also served on the strategic advisory board for GP Strategies Corporation, a global workforce transformation learning solutions provider. Mr. Johnson received his Bachelor of Science degree in Marketing from the Pennsylvania State University.

Leon (Lonnie) O. Moulder, Jr.

Mr. Moulder has served as a member of the Board since November 2011. Mr. Moulder served as Chairman of the Board from June 2013 through November 2023. Mr. Moulder is the Chairman and Chief Executive Office of Zenas BioPhama, a privately held biopharmaceutical company and Managing Member of Tellus BioVentures, LLC, a life science investment fund he founded in March 2019. From May 2010 to January 2019, Mr. Moulder was the co-founder, Chief Executive Officer and a member of the board of directors of TESARO, Inc. (TSRO), a public oncology-focused biopharmaceutical company that was acquired by GlaxoSmithKline plc. From April 2009 to January 2010, Mr. Moulder served as Vice Chairman of the board of directors, President and Chief Executive Officer of Abraxis BioScience, Inc., a biotechnology company. Before that, Mr. Moulder served as Vice Chairman of Eisai Corporation of North America, a pharmaceutical company and wholly owned subsidiary of Eisai Co., Ltd. (OTCMKTS: ESALF), from January 2008 until January 2009, following Eisai Co., Ltd.’s acquisition of MGI PHARMA, Inc., in January 2008. Mr. Moulder served as President and Chief Executive Officer and as a member of the board of directors of MGI PHARMA, Inc. from May 2003 to January 2008. In January 2020, Mr. Moulder joined the board of directors of Zai Lab Ltd. (ZLAB), a biopharmaceutical company. Mr. Moulder earned a B.S. in pharmacy from Temple University and a M.B.A. from the University of Chicago. Mr. Moulder is a Trustee of Temple University and serves as a board member for several privately held biotechnology companies.

Jake R. Nunn

Mr. Nunn is currently a venture partner at SR One Capital Management, a biotech venture capital firm. Previously he was a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a partner from June 2006 until January 2019. From January 2001 to June 2006, Mr. Nunn served as a Partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P., a private equity firm. Previously, Mr. Nunn was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons. Mr. Nunn currently serves on the board of directors of Addex Therapeutics Ltd. (ADXN), Hexima Ltd. (HXL.AX) and Regulus Therapeutics Inc. (RGLS), each a public biopharmaceutical company. Mr. Nunn previously was a Director of Dermira, Inc. (acquired by Eli Lilly and Company), Hyperion Therapeutics, Inc. (acquired by Horizon Pharma PLC) and TriVascular Technologies, Inc. (acquired by Endologix, Inc.). Mr. Nunn received his A.B. in economics from Dartmouth College and his M.B.A. from the Stanford Graduate School of Business. Mr. Nunn holds the Chartered Financial Analyst designation, is a member of the C.F.A. Society of San Francisco, and recently completed the Stanford Graduate School of Business Directors’ Consortium executive education program.

Anne M. Phillips, M.D.

Dr. Phillips was Senior Vice President of Clinical, Medical and Regulatory Affairs at Novo Nordisk Inc. (NVO), a pharmaceutical company, from 2011 until her retirement in August 2022. Previously, she served as a Vice President in various positions at GlaxoSmithKline plc (GSK), which she joined in 1998, and prior to this, Dr. Phillips was Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael’s Hospital in Toronto. She is a Fellow of The Royal College of Physicians and Surgeons of Canada, earned an M.D. from the University of Toronto, and received a B.Sc. from the University of Western Ontario. Dr. Phillips currently serves on the board of directors of Vaccitech, a public company, as well as Carmot Therapeutics, a private company.

Barbara Yanni

Ms. Yanni was Vice President and Chief Licensing Officer at Merck & Co. (MRK), a pharmaceutical company, from November 2001 until her retirement in March 2014. Prior to this, Ms. Yanni served in various roles at Merck including in corporate development, financial evaluation, and tax. Ms. Yanni is currently an independent director on the boards of three public biotechnology companies, Oncorus, Inc. (ONCR), Vaccinex, Inc. (VCNX) and Pharming Group N.V. (Amsterdam: PHARM), and Mesentech, a private biotechnology company. She previously served on the board of directors of Akcea Therapeutics, Inc. (AKCA) and ABIONYX Pharma (Paris: ABNX), both public biotechnology companies, and Symic Holdings, LLC, a private biotechnology company. Ms. Yanni earned a J.D. from Stanford Law School and an A.B. from Wellesley College. She also holds a Masters of Law in Taxation from New York University Law School.